Intermountain rolls out DNA-based test to personalize drug prescribing

Intermountain Precision Genomics, a St. George, Utah-based lab of Salt Lake City-based Intermountain Healthcare, launched the DNA-based RxMatch Anti-Depressant Panel Sept. 5.

The anti-depressant panel is part of the lab's RxMatch series, which leverages pharmacogenomics, the study of how genetics affect an individual's drug response. Intermountain Precision Genomics will pilot the panel in southwest Utah to enable physicians to apply personalized medicine when prescribing medications.

The RxMatch Anti-Depressant Panel is powered by clinical decision support from CNSDose, a startup that uses genetic testing to identify relevant antidepressant medications. With the DNA panel, a physician can use knowledge of a patient's genome to select antidepressant medications.

"The objective of the RxMatch project is to provide the most comprehensive and evidence-based information to the physician, thus decreasing the amount of time and money spent to achieve the correct medication," said David Loughmiller, laboratory manager for Intermountain Precision Genomics.

More articles on data analytics & precision medicine:
UC Davis to use precision medicine in pancreatic cancer care
Kalorama: Apple, Google, IBM make waves in healthcare analytics market
Intermountain, U of Utah Health to develop EHR clinical decision support under $3.8M NCI grant

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months